Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
News and updates for Enanta Pharmaceuticals, Inc. (ENTA) focus on its progress as a clinical-stage biotechnology company developing small molecule drugs for viral infections and immunological diseases. Company press releases frequently highlight clinical data, regulatory designations, pipeline milestones, financial results, capital raises, and intellectual property developments.
Investors following ENTA news can expect detailed coverage of RSV clinical programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an oral L-protein inhibitor. Enanta regularly reports Phase 2 and Phase 2b trial readouts in high-risk adult and pediatric RSV populations, human viral challenge data, and analyses of symptom resolution, viral load reductions, and safety outcomes. Updates also cover Phase 3-enabling activities and interactions with the U.S. Food and Drug Administration on trial design and registration pathways.
News items also track Enanta’s immunology pipeline, such as the nomination of EPS-3903, an oral STAT6 inhibitor for atopic dermatitis and other type 2 immune-driven diseases, and the selection of EDP-978, an oral KIT inhibitor for chronic spontaneous urticaria and other mast cell–driven conditions. Announcements describe preclinical potency, selectivity, and planned IND filings and early clinical timelines, as well as the expansion of discovery programs targeting MRGPRX2.
On the corporate side, ENTA news includes quarterly and annual financial results, commentary on royalty revenue from AbbVie’s HCV regimen MAVYRET/MAVIRET, and disclosures about cash runway expectations. Coverage also includes public equity offerings, underwritten offering terms, and use of proceeds, along with patent litigation developments, such as Enanta’s infringement action in the Unified Patent Court related to its coronavirus protease inhibitor patent. For ongoing insight into ENTA’s clinical, financial, and legal developments, this news feed aggregates the company’s latest official announcements.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported its fiscal Q3 2025 financial results, with total revenue of $18.3 million from royalties on AbbVie's HCV regimen MAVYRET®/MAVIRET®. The company posted a net loss of $18.3 million ($0.85 per share), improving from a $22.7 million loss in Q3 2024.
Key pipeline developments include: completion of enrollment in the RSVHR Phase 2 trial of zelicapavir for RSV treatment with topline data expected in September, ongoing IND-enabling studies for EPS-1421 (KIT inhibitor) for urticaria treatment, and progress toward selecting a STAT6 development candidate in 2H 2025. The company maintains a strong financial position with $204.1 million in cash and marketable securities, projected to fund operations into fiscal 2028.
XtalPi (2228.HK) and DoveTree Medicines have announced a groundbreaking $6 billion strategic collaboration in AI-driven drug discovery. The partnership combines XtalPi's AI and robotics platform with DoveTree's biological expertise to develop novel therapeutics across multiple disease areas.
Under the agreement, DoveTree receives exclusive global rights and will pay XtalPi an upfront payment of $51 million, with $49 million in near-term payments and up to $5.89 billion in milestone payments and tiered royalties. The collaboration will focus on developing first-in-class candidates in oncology, immunology, inflammation, neurology, and metabolic diseases.
DoveTree, founded by renowned drug developer Dr. Gregory Verdine, brings expertise in "drugging the undruggable" targets, while XtalPi contributes its intelligent de novo drug discovery platform spanning multiple modalities including small molecules, biologics, ADCs, and molecular glues.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company focused on developing small molecule drugs for viral infections and immunological diseases, will participate in a virtual fireside chat at the H.C. Wainwright & Co. "HCW@Home" series. The event is scheduled for Tuesday, August 12, 2025 at 1:00 p.m. ET.
Investors can access the live webcast through Enanta's website in the "Events and Presentations" section or via direct registration. A replay will be available after the presentation and archived for at least 30 days.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotech company focused on developing small molecule drugs for viral infections and immunological diseases, will participate in Baird's Biotech Discovery Series. The company's management will engage in a virtual fireside chat on July 22 at 1:30 p.m. ET.
Investors can access the live webcast through the "Events and Presentations" section on Enanta's website. A replay will be available and archived for at least 30 days after the event.
Enanta Pharmaceuticals (NASDAQ: ENTA), a clinical-stage biotech company focused on developing small molecule drugs for viral infections and immunological diseases, has announced that its President and CEO, Jay R. Luly, Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference. The presentation is scheduled for June 5, 2025, at 8:10 a.m. ET in New York. Investors can access the live webcast through Enanta's website, and a replay will be available for at least 30 days after the event.
Enanta Pharmaceuticals (NASDAQ:ENTA) has announced that data from their Phase 2a human challenge study of EDP-323, a first-in-class oral RSV treatment, will be presented at ESCMID Global 2025 in Vienna, Austria. The presentation will showcase results from the study, which were initially announced in September 2024, including new data on respiratory mucus production.
EDP-323 is a non-nucleoside small-molecule inhibitor targeting the RSV polymerase (L-protein). The ePoster presentation, titled 'EDP-323, a First-in-Class, Oral, RSV L-Protein Inhibitor Reduces Disease Severity (Respiratory Mucus Production) and Accelerates Viral Clearance in a Human Viral Challenge Study,' will be presented by Dr. John P. DeVincenzo on April 13, 2025, at 8:30 a.m. CEST.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotechnology company focused on developing small molecule drugs for virology and immunology indications, has announced its upcoming participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference.
The management team will deliver their presentation on Thursday, March 27, 2025, at 11:00 a.m. ET. Interested parties can access the live webcast through the 'Events and Presentations' section on the 'Investors' page of Enanta's website. A replay will be available post-presentation and remain accessible for a minimum of 30 days.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced its upcoming presentations at the 13th International RSV Symposium (RSV 2025) in Iguazu Falls, Brazil, from March 12-15. The company will showcase four presentations highlighting its respiratory syncytial virus (RSV) program:
The main oral presentation will feature results from a Phase 2 human challenge study of EDP-323, an RSV L-protein inhibitor, scheduled for March 14. A late-breaker poster will present data from a Phase 2 study of zelicapavir, an N-protein inhibitor, for RSV treatment in young children.
Two additional poster presentations will focus on: (1) distinctions among fusion, N, and L inhibitors regarding preclinical antiviral effect and resistance profiles, and (2) PK and PK/PD results from the EDP-323 Phase 2 human challenge study. All presentations will be delivered at the Bourbon Cataratas do Iguazu venue.